- Home
- AMRN vs EIC Comparison
AMRN vs EIC Comparison
Compare AMRN & EIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMRN
- EIC
- Stock Information
- Founded
- AMRN 1989
- EIC N/A
- Country
- AMRN Ireland
- EIC United States
- Employees
- AMRN N/A
- EIC N/A
- Industry
- AMRN Biotechnology: Pharmaceutical Preparations
- EIC Finance/Investors Services
- Sector
- AMRN Health Care
- EIC Finance
- Exchange
- AMRN Nasdaq
- EIC Nasdaq
- Market Cap
- AMRN 302.0M
- EIC 334.1M
- IPO Year
- AMRN 1993
- EIC 2019
- Fundamental
- Price
- AMRN $19.18
- EIC $12.70
- Analyst Decision
- AMRN Strong Sell
- EIC
- Analyst Count
- AMRN 1
- EIC 0
- Target Price
- AMRN $12.00
- EIC N/A
- AVG Volume (30 Days)
- AMRN 144.3K
- EIC 154.6K
- Earning Date
- AMRN 10-29-2025
- EIC 11-13-2025
- Dividend Yield
- AMRN N/A
- EIC 12.28%
- EPS Growth
- AMRN N/A
- EIC N/A
- EPS
- AMRN N/A
- EIC 0.70
- Revenue
- AMRN $219,361,000.00
- EIC $55,581,156.00
- Revenue This Year
- AMRN N/A
- EIC $37.84
- Revenue Next Year
- AMRN N/A
- EIC $23.33
- P/E Ratio
- AMRN N/A
- EIC $18.25
- Revenue Growth
- AMRN N/A
- EIC 56.39
- 52 Week Low
- AMRN $7.08
- EIC $12.10
- 52 Week High
- AMRN $20.90
- EIC $16.71
- Technical
- Relative Strength Index (RSI)
- AMRN 58.42
- EIC 48.41
- Support Level
- AMRN $19.02
- EIC $12.13
- Resistance Level
- AMRN $20.90
- EIC $12.52
- Average True Range (ATR)
- AMRN 0.93
- EIC 0.24
- MACD
- AMRN -0.15
- EIC 0.03
- Stochastic Oscillator
- AMRN 40.81
- EIC 79.73
About AMRN Amarin Corporation plc
Amarin Corp PLC is a biopharmaceutical company. It is focused on the commercialization and development of therapeutics to improve cardiovascular, or CV, health and reduce CV risk. Its commercialized product includes Vascepa.
About EIC Eagle Point Income Company Inc.
Eagle Point Income Co Inc is a closed-end management investment company. Its primary investment objective is to generate high current income, with a secondary objective to generate capital appreciation. The Company seeks to achieve its investment objectives by investing in junior debt tranches of collateralized loan obligations, or "CLOs," that are collateralized by a portfolio consisting of below-investment grade U.S. senior secured loans with a large number of distinct underlying borrowers across various industry sectors.